Rai Ajit K Srivastava

Summary

Publications

  1. pmc AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases
    Rai Ajit K Srivastava
    Esperion Therapeutics Inc, Plymouth, MI 48170, USA
    J Lipid Res 53:2490-514. 2012
  2. pmc ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
    Sergey Filippov
    Esperion Therapeutics Inc, Plymouth, MI 48170, USA sfi
    J Lipid Res 54:2095-108. 2013
  3. pmc AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
    Stephen L Pinkosky
    Esperion Therapeutics, Inc, Plymouth, MI, USA
    J Lipid Res 54:134-51. 2013

Collaborators

  • Stephen L Pinkosky
  • Sergey Filippov
  • Cheryl D Bradshaw
  • Jeffrey C Hanselman
  • Roger S Newton
  • Timothy R Hurley
  • Clay T Cramer
  • Mark A Spahr
  • Khosrow Adeli
  • Mark Naples
  • Richard J Lister
  • Ashley F Brant
  • Jacob L Houghton
  • Chris Baker
  • Catherine Pawloski

Detail Information

Publications3

  1. pmc AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases
    Rai Ajit K Srivastava
    Esperion Therapeutics Inc, Plymouth, MI 48170, USA
    J Lipid Res 53:2490-514. 2012
    ..The mode of action of AMPK activators, mechanism of anti-inflammatory activities, and preclinical and clinical findings as well as future prospects of AMPK as a drug target in treating cardio-metabolic disease are discussed...
  2. pmc ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
    Sergey Filippov
    Esperion Therapeutics Inc, Plymouth, MI 48170, USA sfi
    J Lipid Res 54:2095-108. 2013
    ..Thus, ETC-1002 may provide further clinical benefits for patients with cardiometabolic risk factors by reducing systemic inflammation linked to insulin resistance and vascular complications of metabolic syndrome. ..
  3. pmc AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
    Stephen L Pinkosky
    Esperion Therapeutics, Inc, Plymouth, MI, USA
    J Lipid Res 54:134-51. 2013
    ..ETC-1002 offers promise as a novel therapeutic approach to improve multiple risk factors associated with metabolic syndrome and benefit patients with cardiovascular disease...